JARDIANCE^® provides triple protection in your patients with CRM conditions:

Expert's Opinion on How is eGFR slope a viable surrogate endpoint for kidney disease progression in clinical trials? (Brendon Neuen)

20/08/2024 | Author: Boehringer Ingelheim

Document ID: PC-MY-103824